Please login to the form below

Not currently logged in
Email:
Password:

relapsing multiple sclerosis

This page shows the latest relapsing multiple sclerosis news and features for those working in and with pharma, biotech and healthcare.

Bristol Myers Squibb announces positive trial results for treatment of MS

Bristol Myers Squibb announces positive trial results for treatment of MS

Bristol Myers Squibb (BMS) announced that analysis from two phase 3 trials of Zeposia (ozanimod) showed that early use of the treatment demonstrated cognitive benefits in people with relapsing multiple sclerosis ... for the treatment of adult patients

Latest news

More from news
Approximately 1 fully matching, plus 71 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    of B and T cells outside the lymph nodes, to treat relapsing forms of multiple sclerosis. ... phase 3 development to treat relapsing forms of multiple sclerosis.

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – development. $595. Xenoport/ Dr Reddy's. XP-23829 for plaque psoriasis and relapsing multiple sclerosis.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...